Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-05

AUTHORS

Ahmed Hamed Salem, Nimita Dave, Thomas Marbury, Beibei Hu, Dale Miles, Suresh K Agarwal, Orlando F Bueno, Rajeev M Menon

ABSTRACT

INTRODUCTION: Venetoclax is a selective B cell lymphoma-2 inhibitor. It is approved for treatment of chronic lymphocytic leukemia and is being investigated for other hematological malignancies. Venetoclax is predominantly eliminated by the liver; therefore, there is a need to investigate the effect of hepatic insufficiency on venetoclax pharmacokinetics. METHODS: A phase I study was carried out in 24 women with normal hepatic function or mild, moderate, or severe hepatic impairment (based on Child-Pugh scores), who received a single 50 mg dose of venetoclax with a low-fat meal. Blood samples were collected up to 120 h after venetoclax administration. Pharmacokinetic parameters were estimated using non-compartmental methods. RESULTS: Venetoclax maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in subjects with mild or moderate hepatic impairment were similar to subjects with normal hepatic function. Mean venetoclax AUC in subjects with severe hepatic impairment was 2.3- to 2.7-fold higher than in subjects with normal hepatic function. The half-life of venetoclax in subjects with severe hepatic impairment was approximately two-fold longer than in subjects with normal hepatic function and subjects with mild or moderate hepatic impairment. Unbound fractions of venetoclax in subjects with mild, moderate, and severe hepatic impairment were similar to the subjects with normal hepatic function. No significant adverse safety events were reported. CONCLUSIONS: No venetoclax dosage adjustment is required in subjects with mild or moderate hepatic impairment. In subjects with severe hepatic impairment, a 50% dose reduction of venetoclax is recommended to account for higher exposures and the longer half-life. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40262-019-00746-4

DOI

http://dx.doi.org/10.1007/s40262-019-00746-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113185290

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30949874


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ain Shams University", 
          "id": "https://www.grid.ac/institutes/grid.7269.a", 
          "name": [
            "AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA. ahmed.salem@abbvie.com.", 
            "Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. ahmed.salem@abbvie.com."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salem", 
        "givenName": "Ahmed Hamed", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AbbVie (United States)", 
          "id": "https://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dave", 
        "givenName": "Nimita", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orlando Clinical Research Center", 
          "id": "https://www.grid.ac/institutes/grid.477729.8", 
          "name": [
            "Orlando Clinical Research Center, Orlando, FL, 32809-3017, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marbury", 
        "givenName": "Thomas", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AbbVie (United States)", 
          "id": "https://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hu", 
        "givenName": "Beibei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech Inc., South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miles", 
        "givenName": "Dale", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AbbVie (United States)", 
          "id": "https://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agarwal", 
        "givenName": "Suresh K", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AbbVie (United States)", 
          "id": "https://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bueno", 
        "givenName": "Orlando F", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AbbVie (United States)", 
          "id": "https://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Menon", 
        "givenName": "Rajeev M", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-2873", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000021723"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcph.858", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000538203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.70.4320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007680380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcph.821", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009315124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1513257", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010434640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-016-0453-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011190437", 
          "https://doi.org/10.1007/s40262-016-0453-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-016-0453-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011190437", 
          "https://doi.org/10.1007/s40262-016-0453-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12248-016-9927-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012914847", 
          "https://doi.org/10.1208/s12248-016-9927-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-008-0553-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013600709", 
          "https://doi.org/10.1007/s00228-008-0553-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-008-0553-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013600709", 
          "https://doi.org/10.1007/s00228-008-0553-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hon.2373", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017477101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcph.741", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023810821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3144-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027208212", 
          "https://doi.org/10.1007/s00280-016-3144-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3144-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027208212", 
          "https://doi.org/10.1007/s00280-016-3144-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcph.730", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033198266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-016-0485-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036144289", 
          "https://doi.org/10.1007/s40261-016-0485-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-016-0485-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036144289", 
          "https://doi.org/10.1007/s40261-016-0485-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.30.2307", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036193124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.116.071613", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038411197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bcp.13175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043937102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bcp.13175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043937102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2017.01.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083423676"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2017.01.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083423676"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt.712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084862864"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000522", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085739515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000522", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085739515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10428194.2017.1361024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091162761"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2017-06-788323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091433225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/00498254.2017.1381779", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092192882"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpdd.395", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092326657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpdd.395", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092326657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30909-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099653743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2403-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100197803", 
          "https://doi.org/10.1007/s00228-017-2403-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.078915", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100800491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcph.1127", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103428455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.76.6840", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103752943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy256", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105860536"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpdd.610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106420587"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-018-0793-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107273518", 
          "https://doi.org/10.1007/s12325-018-0793-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-05", 
    "datePublishedReg": "2019-04-05", 
    "description": "INTRODUCTION: Venetoclax is a selective B\u00a0cell lymphoma-2 inhibitor. It is approved for treatment of chronic lymphocytic leukemia and is being investigated for other hematological malignancies. Venetoclax is predominantly eliminated by the liver; therefore, there is a need to investigate the effect of hepatic insufficiency on venetoclax pharmacokinetics.\nMETHODS: A phase\u00a0I study was carried out in 24 women with normal hepatic function or mild, moderate, or severe hepatic impairment (based on Child-Pugh scores), who received a single 50 mg\u00a0dose of venetoclax with a low-fat meal. Blood samples were collected up to 120\u00a0h after venetoclax administration. Pharmacokinetic parameters were estimated using non-compartmental methods.\nRESULTS: Venetoclax maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in subjects with mild or moderate hepatic impairment were similar to subjects with normal hepatic function. Mean venetoclax AUC in subjects with severe hepatic impairment was 2.3- to 2.7-fold higher than in subjects with normal hepatic function. The half-life of venetoclax in subjects with severe hepatic impairment was approximately two-fold longer than in subjects with normal hepatic function and subjects with\u00a0mild or moderate hepatic impairment. Unbound fractions of venetoclax in subjects with mild, moderate, and severe hepatic impairment were similar to the subjects with normal hepatic function. No significant adverse safety events were reported.\nCONCLUSIONS: No venetoclax dosage adjustment is required in subjects with mild or moderate hepatic impairment. In subjects with severe hepatic impairment, a 50% dose reduction of venetoclax is recommended to account for higher exposures and the longer half-life.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40262-019-00746-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085321", 
        "issn": [
          "0312-5963", 
          "1179-1926"
        ], 
        "name": "Clinical Pharmacokinetics", 
        "type": "Periodical"
      }
    ], 
    "name": "Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.", 
    "productId": [
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30949874"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7606849"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40262-019-00746-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113185290"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40262-019-00746-4", 
      "https://app.dimensions.ai/details/publication/pub.1113185290"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000372_0000000372/records_117100_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s40262-019-00746-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40262-019-00746-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40262-019-00746-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40262-019-00746-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40262-019-00746-4'


 

This table displays all metadata directly associated to this object as RDF triples.

209 TRIPLES      20 PREDICATES      55 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40262-019-00746-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Na036b29a72274d35938dd8bb2ae3f5b9
4 schema:citation sg:pub.10.1007/s00228-008-0553-z
5 sg:pub.10.1007/s00228-017-2403-3
6 sg:pub.10.1007/s00280-016-3144-1
7 sg:pub.10.1007/s12325-018-0793-y
8 sg:pub.10.1007/s40261-016-0485-9
9 sg:pub.10.1007/s40262-016-0453-9
10 sg:pub.10.1208/s12248-016-9927-9
11 https://doi.org/10.1002/cpdd.395
12 https://doi.org/10.1002/cpdd.610
13 https://doi.org/10.1002/cpt.712
14 https://doi.org/10.1002/hon.2373
15 https://doi.org/10.1002/jcph.1127
16 https://doi.org/10.1002/jcph.730
17 https://doi.org/10.1002/jcph.741
18 https://doi.org/10.1002/jcph.821
19 https://doi.org/10.1002/jcph.858
20 https://doi.org/10.1016/j.clinthera.2017.01.003
21 https://doi.org/10.1016/s1470-2045(17)30909-9
22 https://doi.org/10.1056/nejmoa1513257
23 https://doi.org/10.1080/00498254.2017.1381779
24 https://doi.org/10.1080/10428194.2017.1361024
25 https://doi.org/10.1093/annonc/mdy256
26 https://doi.org/10.1097/cad.0000000000000522
27 https://doi.org/10.1111/bcp.13175
28 https://doi.org/10.1124/dmd.116.071613
29 https://doi.org/10.1124/dmd.117.078915
30 https://doi.org/10.1158/1078-0432.ccr-11-2873
31 https://doi.org/10.1182/blood-2017-06-788323
32 https://doi.org/10.1200/jco.2010.30.2307
33 https://doi.org/10.1200/jco.2016.70.4320
34 https://doi.org/10.1200/jco.2017.76.6840
35 schema:datePublished 2019-04-05
36 schema:datePublishedReg 2019-04-05
37 schema:description INTRODUCTION: Venetoclax is a selective B cell lymphoma-2 inhibitor. It is approved for treatment of chronic lymphocytic leukemia and is being investigated for other hematological malignancies. Venetoclax is predominantly eliminated by the liver; therefore, there is a need to investigate the effect of hepatic insufficiency on venetoclax pharmacokinetics. METHODS: A phase I study was carried out in 24 women with normal hepatic function or mild, moderate, or severe hepatic impairment (based on Child-Pugh scores), who received a single 50 mg dose of venetoclax with a low-fat meal. Blood samples were collected up to 120 h after venetoclax administration. Pharmacokinetic parameters were estimated using non-compartmental methods. RESULTS: Venetoclax maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in subjects with mild or moderate hepatic impairment were similar to subjects with normal hepatic function. Mean venetoclax AUC in subjects with severe hepatic impairment was 2.3- to 2.7-fold higher than in subjects with normal hepatic function. The half-life of venetoclax in subjects with severe hepatic impairment was approximately two-fold longer than in subjects with normal hepatic function and subjects with mild or moderate hepatic impairment. Unbound fractions of venetoclax in subjects with mild, moderate, and severe hepatic impairment were similar to the subjects with normal hepatic function. No significant adverse safety events were reported. CONCLUSIONS: No venetoclax dosage adjustment is required in subjects with mild or moderate hepatic impairment. In subjects with severe hepatic impairment, a 50% dose reduction of venetoclax is recommended to account for higher exposures and the longer half-life.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf sg:journal.1085321
42 schema:name Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
43 schema:productId Na9874d1d2ba6426682f53b6253f77d0e
44 Nbd1c38945d4c44be92a24e70c2d7d73a
45 Nd39606f0b5314b8e88075417929efd0e
46 Ne5c333386c67487ba14e434ebd4d9191
47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113185290
48 https://doi.org/10.1007/s40262-019-00746-4
49 schema:sdDatePublished 2019-04-11T14:18
50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
51 schema:sdPublisher N3ff898145de2499eb9b309b3fe12f2a8
52 schema:url http://link.springer.com/10.1007/s40262-019-00746-4
53 sgo:license sg:explorer/license/
54 sgo:sdDataset articles
55 rdf:type schema:ScholarlyArticle
56 N24ae928b189d4262ae09fb74c94f3c06 rdf:first Nf7d05c8cf43f458aa75285730a64b4a8
57 rdf:rest Ne1ccb3cf2eae4268b41241802e6f93a1
58 N251ab3b4b48844718b3b3d034a317c3f schema:affiliation https://www.grid.ac/institutes/grid.7269.a
59 schema:familyName Salem
60 schema:givenName Ahmed Hamed
61 rdf:type schema:Person
62 N382f15001a954907bbc4faf64dcfc5bf schema:affiliation https://www.grid.ac/institutes/grid.431072.3
63 schema:familyName Bueno
64 schema:givenName Orlando F
65 rdf:type schema:Person
66 N3d99a6954d9b4c3f9267ea0851b6101d schema:affiliation https://www.grid.ac/institutes/grid.431072.3
67 schema:familyName Hu
68 schema:givenName Beibei
69 rdf:type schema:Person
70 N3e5ab476fca64561a621fb28b34396ad schema:affiliation https://www.grid.ac/institutes/grid.431072.3
71 schema:familyName Agarwal
72 schema:givenName Suresh K
73 rdf:type schema:Person
74 N3ff898145de2499eb9b309b3fe12f2a8 schema:name Springer Nature - SN SciGraph project
75 rdf:type schema:Organization
76 N5bc823af35ba471b8d185f05462b17b7 rdf:first N382f15001a954907bbc4faf64dcfc5bf
77 rdf:rest Nb303ddbab11145f7a35712f3d79d76d9
78 N7532c3e5955047c8b566127e31b99945 schema:affiliation https://www.grid.ac/institutes/grid.431072.3
79 schema:familyName Menon
80 schema:givenName Rajeev M
81 rdf:type schema:Person
82 N8d4c517a33504e4b91df20cbe6fb841e rdf:first N3d99a6954d9b4c3f9267ea0851b6101d
83 rdf:rest Na895f4098782415695c8070a2bf8fa91
84 Na036b29a72274d35938dd8bb2ae3f5b9 rdf:first N251ab3b4b48844718b3b3d034a317c3f
85 rdf:rest N24ae928b189d4262ae09fb74c94f3c06
86 Na40f6ad826364286a9bb052f1bfc3fb8 schema:affiliation https://www.grid.ac/institutes/grid.477729.8
87 schema:familyName Marbury
88 schema:givenName Thomas
89 rdf:type schema:Person
90 Na895f4098782415695c8070a2bf8fa91 rdf:first Ne339f1abe49c421cab536ee2528a1be6
91 rdf:rest Nb1a568db641a4fe1baf7f24df9f100dc
92 Na9874d1d2ba6426682f53b6253f77d0e schema:name doi
93 schema:value 10.1007/s40262-019-00746-4
94 rdf:type schema:PropertyValue
95 Nb1a568db641a4fe1baf7f24df9f100dc rdf:first N3e5ab476fca64561a621fb28b34396ad
96 rdf:rest N5bc823af35ba471b8d185f05462b17b7
97 Nb303ddbab11145f7a35712f3d79d76d9 rdf:first N7532c3e5955047c8b566127e31b99945
98 rdf:rest rdf:nil
99 Nbd1c38945d4c44be92a24e70c2d7d73a schema:name pubmed_id
100 schema:value 30949874
101 rdf:type schema:PropertyValue
102 Nd39606f0b5314b8e88075417929efd0e schema:name nlm_unique_id
103 schema:value 7606849
104 rdf:type schema:PropertyValue
105 Ne1ccb3cf2eae4268b41241802e6f93a1 rdf:first Na40f6ad826364286a9bb052f1bfc3fb8
106 rdf:rest N8d4c517a33504e4b91df20cbe6fb841e
107 Ne339f1abe49c421cab536ee2528a1be6 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
108 schema:familyName Miles
109 schema:givenName Dale
110 rdf:type schema:Person
111 Ne5c333386c67487ba14e434ebd4d9191 schema:name dimensions_id
112 schema:value pub.1113185290
113 rdf:type schema:PropertyValue
114 Nf7d05c8cf43f458aa75285730a64b4a8 schema:affiliation https://www.grid.ac/institutes/grid.431072.3
115 schema:familyName Dave
116 schema:givenName Nimita
117 rdf:type schema:Person
118 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
119 schema:name Medical and Health Sciences
120 rdf:type schema:DefinedTerm
121 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
122 schema:name Clinical Sciences
123 rdf:type schema:DefinedTerm
124 sg:journal.1085321 schema:issn 0312-5963
125 1179-1926
126 schema:name Clinical Pharmacokinetics
127 rdf:type schema:Periodical
128 sg:pub.10.1007/s00228-008-0553-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1013600709
129 https://doi.org/10.1007/s00228-008-0553-z
130 rdf:type schema:CreativeWork
131 sg:pub.10.1007/s00228-017-2403-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100197803
132 https://doi.org/10.1007/s00228-017-2403-3
133 rdf:type schema:CreativeWork
134 sg:pub.10.1007/s00280-016-3144-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027208212
135 https://doi.org/10.1007/s00280-016-3144-1
136 rdf:type schema:CreativeWork
137 sg:pub.10.1007/s12325-018-0793-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1107273518
138 https://doi.org/10.1007/s12325-018-0793-y
139 rdf:type schema:CreativeWork
140 sg:pub.10.1007/s40261-016-0485-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036144289
141 https://doi.org/10.1007/s40261-016-0485-9
142 rdf:type schema:CreativeWork
143 sg:pub.10.1007/s40262-016-0453-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011190437
144 https://doi.org/10.1007/s40262-016-0453-9
145 rdf:type schema:CreativeWork
146 sg:pub.10.1208/s12248-016-9927-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012914847
147 https://doi.org/10.1208/s12248-016-9927-9
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1002/cpdd.395 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092326657
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1002/cpdd.610 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106420587
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1002/cpt.712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084862864
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1002/hon.2373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017477101
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1002/jcph.1127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103428455
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1002/jcph.730 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033198266
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1002/jcph.741 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023810821
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1002/jcph.821 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009315124
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1002/jcph.858 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000538203
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1016/j.clinthera.2017.01.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083423676
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1016/s1470-2045(17)30909-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099653743
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1056/nejmoa1513257 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010434640
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1080/00498254.2017.1381779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092192882
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1080/10428194.2017.1361024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091162761
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1093/annonc/mdy256 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105860536
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1097/cad.0000000000000522 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085739515
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1111/bcp.13175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043937102
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1124/dmd.116.071613 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038411197
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1124/dmd.117.078915 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100800491
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1158/1078-0432.ccr-11-2873 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000021723
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1182/blood-2017-06-788323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091433225
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1200/jco.2010.30.2307 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036193124
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1200/jco.2016.70.4320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007680380
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1200/jco.2017.76.6840 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103752943
196 rdf:type schema:CreativeWork
197 https://www.grid.ac/institutes/grid.418158.1 schema:alternateName Roche (United States)
198 schema:name Genentech Inc., South San Francisco, CA, 94080, USA.
199 rdf:type schema:Organization
200 https://www.grid.ac/institutes/grid.431072.3 schema:alternateName AbbVie (United States)
201 schema:name AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
202 rdf:type schema:Organization
203 https://www.grid.ac/institutes/grid.477729.8 schema:alternateName Orlando Clinical Research Center
204 schema:name Orlando Clinical Research Center, Orlando, FL, 32809-3017, USA.
205 rdf:type schema:Organization
206 https://www.grid.ac/institutes/grid.7269.a schema:alternateName Ain Shams University
207 schema:name AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA. ahmed.salem@abbvie.com.
208 Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. ahmed.salem@abbvie.com.
209 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...